Sapience Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Team
    • Directors
    • Advisors
  • Our Approach
    • Overview
    • Therapeutic Approach
    • Discovery Platform
  • Pipeline
    • Overview
    • ST101
    • β-Catenin Antagonist
    • cJun Antagonist
    • cMyc Antagonist
    • FoxP3 Antagonist
    • Expanded Access
  • Partnering
  • Careers
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Contact

Press Releases

News & Events

News & Events

  • Press Releases
  • Events
  • Publications
  • Presentations
  • Email Alerts
May 12, 2022 8:04am EDT

Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022

May 03, 2022 8:00am EDT

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma

Apr 11, 2022 10:00am EDT

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways

Mar 31, 2022 8:00am EDT

Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs

Mar 15, 2022 4:05pm EDT

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect

Mar 09, 2022 8:00am EST

Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

Feb 15, 2022 8:00am EST

Sapience Therapeutics Strengthens Executive Team with Appointments of Marisa Frackman as Chief Financial Officer and Seth I. Rubin as General Counsel

Feb 03, 2022 4:05pm EST

Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference

Jan 06, 2022 8:00am EST

Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101

Dec 15, 2021 8:16am EST

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma

  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
RSS
© 2022 Sapience Therapeutics, Inc. All Rights Reserved.
linkedin
Privacy Policy Disclaimer Sitemap